Correction: consensus on criteria for acromegaly diagnosis and remission (Pituitary, (2024), 27, 1, (7-22), 10.1007/s11102-023-01360-1)

Acromegaly Consensus Group

doi:10.1007/s11102-023-01373-w

Correction: consensus on criteria for acromegaly diagnosis and remission (Pituitary, (2024), 27, 1, (7-22), 10.1007/s11102-023-01360-1)

Acromegaly Consensus Group

Neurological Surgery

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

. In this article the statement in the Funding information section was incorrectly given as 'The 14th Acromegaly Consensus Conference was supported by unrestricted educational grants from Amolyt Pharma, Amryt Pharma, Basecamp Bio, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, and Recordati Rare Diseases’ and should have read The 14th Acromegaly Consensus Conference was supported by unrestricted educational grants from Amolyt Pharma, Amryt Pharma, Basecamp Bio, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, Pfizer, and Recordati Rare Diseases. The original article has been corrected.

Original language	English (US)
Pages (from-to)	88
Number of pages	1
Journal	Pituitary
Volume	27
Issue number	1
DOIs	https://doi.org/10.1007/s11102-023-01373-w
State	Published - Feb 2024

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1007/s11102-023-01373-w

Cite this

@article{b88a9e703ab1432d9cd1580673545567,

title = "Correction: consensus on criteria for acromegaly diagnosis and remission (Pituitary, (2024), 27, 1, (7-22), 10.1007/s11102-023-01360-1)",

abstract = ". In this article the statement in the Funding information section was incorrectly given as 'The 14th Acromegaly Consensus Conference was supported by unrestricted educational grants from Amolyt Pharma, Amryt Pharma, Basecamp Bio, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, and Recordati Rare Diseases{\textquoteright} and should have read The 14th Acromegaly Consensus Conference was supported by unrestricted educational grants from Amolyt Pharma, Amryt Pharma, Basecamp Bio, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, Pfizer, and Recordati Rare Diseases. The original article has been corrected.",

author = "{Acromegaly Consensus Group} and Andrea Giustina and Nienke Biermasz and Casanueva, {Felipe F.} and Maria Fleseriu and Pietro Mortini and Christian Strasburger and {van der Lely}, {A. J.} and John Wass and Shlomo Melmed",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2024",

month = feb,

doi = "10.1007/s11102-023-01373-w",

language = "English (US)",

volume = "27",

pages = "88",

journal = "Pituitary",

issn = "1386-341X",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Correction

T2 - consensus on criteria for acromegaly diagnosis and remission (Pituitary, (2024), 27, 1, (7-22), 10.1007/s11102-023-01360-1)

AU - Acromegaly Consensus Group

AU - Giustina, Andrea

AU - Biermasz, Nienke

AU - Casanueva, Felipe F.

AU - Fleseriu, Maria

AU - Mortini, Pietro

AU - Strasburger, Christian

AU - van der Lely, A. J.

AU - Wass, John

AU - Melmed, Shlomo

PY - 2024/2

Y1 - 2024/2

N2 - . In this article the statement in the Funding information section was incorrectly given as 'The 14th Acromegaly Consensus Conference was supported by unrestricted educational grants from Amolyt Pharma, Amryt Pharma, Basecamp Bio, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, and Recordati Rare Diseases’ and should have read The 14th Acromegaly Consensus Conference was supported by unrestricted educational grants from Amolyt Pharma, Amryt Pharma, Basecamp Bio, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, Pfizer, and Recordati Rare Diseases. The original article has been corrected.

AB - . In this article the statement in the Funding information section was incorrectly given as 'The 14th Acromegaly Consensus Conference was supported by unrestricted educational grants from Amolyt Pharma, Amryt Pharma, Basecamp Bio, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, and Recordati Rare Diseases’ and should have read The 14th Acromegaly Consensus Conference was supported by unrestricted educational grants from Amolyt Pharma, Amryt Pharma, Basecamp Bio, Crinetics Pharmaceuticals, Ionis Pharmaceuticals, Novo Nordisk, Pfizer, and Recordati Rare Diseases. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85178952434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85178952434&partnerID=8YFLogxK

U2 - 10.1007/s11102-023-01373-w

DO - 10.1007/s11102-023-01373-w

M3 - Comment/debate

C2 - 38052967

AN - SCOPUS:85178952434

SN - 1386-341X

VL - 27

SP - 88

JO - Pituitary

JF - Pituitary

IS - 1

ER -

Correction: consensus on criteria for acromegaly diagnosis and remission (Pituitary, (2024), 27, 1, (7-22), 10.1007/s11102-023-01360-1)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this